141 related articles for article (PubMed ID: 21795452)
1. Management of papillary thyroid cancer patients in absence of postoperative radioiodine remnant ablation: tailoring follow-up by neck sonography.
Durante C; Filetti S
J Clin Endocrinol Metab; 2011 Oct; 96(10):3059-61. PubMed ID: 21795452
[No Abstract] [Full Text] [Related]
2. Strategies of radioiodine ablation in patients with low-risk thyroid cancer.
Schlumberger M; Catargi B; Borget I; Deandreis D; Zerdoud S; Bridji B; Bardet S; Leenhardt L; Bastie D; Schvartz C; Vera P; Morel O; Benisvy D; Bournaud C; Bonichon F; Dejax C; Toubert ME; Leboulleux S; Ricard M; Benhamou E;
N Engl J Med; 2012 May; 366(18):1663-73. PubMed ID: 22551127
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 800 and 3700 MBq iodine-131 for the postoperative ablation of thyroid remnant in patients with low-risk differentiated thyroid cancer.
Caglar M; Bozkurt FM; Akca CK; Vargol SE; Bayraktar M; Ugur O; Karaağaoğlu E
Nucl Med Commun; 2012 Mar; 33(3):268-74. PubMed ID: 22205241
[TBL] [Abstract][Full Text] [Related]
4. Thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma in children.
Antonelli A; Miccoli P; Fallahi P; Ferrari SM; Grosso M; Boni G; Berti P
Surgery; 2006 Dec; 140(6):1035-41; discussion 1041-2. PubMed ID: 17188154
[No Abstract] [Full Text] [Related]
5. Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine 131I and recombinant human thyroid stimulating hormone.
Rudavsky AZ; Freeman LM
J Clin Endocrinol Metab; 1997 Jan; 82(1):11-4. PubMed ID: 8989223
[No Abstract] [Full Text] [Related]
6. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
[TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
9. Protocol for thyroid remnant ablation after recombinant TSH in thyroid carcinoma.
Pitoia F; El Tamer E; Salvai ME; Niepomniszcze H
Medicina (B Aires); 2009; 69(1 Pt 2):148-52. PubMed ID: 19414296
[TBL] [Abstract][Full Text] [Related]
10. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment.
Bonnet S; Hartl D; Leboulleux S; Baudin E; Lumbroso JD; Al Ghuzlan A; Chami L; Schlumberger M; Travagli JP
J Clin Endocrinol Metab; 2009 Apr; 94(4):1162-7. PubMed ID: 19116234
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine therapy for differentiated thyroid carcinoma.
Connor CS; Thomas JH; Robinson RG; Preston DF; Hermreck AS
Am J Surg; 1988 Dec; 156(6):519-21. PubMed ID: 3202264
[TBL] [Abstract][Full Text] [Related]
13. Commentary: Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Terris DJ
Head Neck; 2010 Jun; 32(6):698-9. PubMed ID: 20187017
[No Abstract] [Full Text] [Related]
14. [Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma].
Díez JJ; Grande E; Iglesias P
Med Clin (Barc); 2015 Jan; 144(1):35-41. PubMed ID: 24613061
[TBL] [Abstract][Full Text] [Related]
15. False-positive uptake of I-131 in a laryngocele mimicking thyroid remnant after thyroidectomy for papillary thyroid carcinoma.
Schmidt M; Dietlein M; Schröder U; Schicha H
Clin Nucl Med; 2006 Nov; 31(11):716-7. PubMed ID: 17053394
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
17. (18)F-FDG PET discovered an elusive cervical inflammatory pseudotumor associated with a papillary thyroid cancer.
Modesto J; Gardeazabal I; Santos AM; Galofré JC
Endocrinol Nutr; 2014; 61(6):338-40. PubMed ID: 24721020
[No Abstract] [Full Text] [Related]
18. Treatment of persistent or recurrent papillary carcinoma of the thyroid--the good, the bad, and the unknown.
Udelsman R
J Clin Endocrinol Metab; 2010 May; 95(5):2061-3. PubMed ID: 20444934
[No Abstract] [Full Text] [Related]
19. Nuclear medicine approaches in the monitoring of thyroid cancer patients.
Sergieva S; Hadjieva T; Doldurova M; Stefanova S; Dudov A
J BUON; 2006; 11(4):511-8. PubMed ID: 17309186
[TBL] [Abstract][Full Text] [Related]
20. Assessment of recurrence rates in papillary thyroid microcarcinoma patients with and without histopathological risk factors after radioiodine ablation treatment.
Soydal C; Araz M; Ozkan E; Arslantaş E; Kucuk ON; Aras G
Nucl Med Commun; 2015 Feb; 36(2):109-13. PubMed ID: 25321158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
